Trial Profile
A prospective, randomised, placebo controlled, multicenter study of the efficacy and safety of rituximab as induction therapy together with tacrolimus, mycophenolate mofetil and steroids for patients undergoing renal transplantation.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Apr 2013
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Corticosteroids; Mycophenolate mofetil; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 29 Nov 2007 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Oct 2006 New trial record.